Novo Nordisk launches international survey into the psychosocial effects of living with haemophilia

Novo NordiskNovo Nordisk announced today the start of a global survey into the psychological and social effects of haemophilia. The study, named HERO (Haemophilia Experiences, Results and Opportunities), will assess factors such as the attitudes of patients and their families to diagnosis and treatment, their aspirations and the social context of haemophilia. The study will include responses from over 1,300 people from 12 countries, and is the largest international research project ever carried out into the social and psychological impact of this condition.

The launch of the study marks World Haemophilia Day April 17 and the first findings will be presented at the World Federation of Haemophilia Congress in Buenos Aires, Argentina from 10 to 14 July 2010.

The study is divided into two phases. The first phase, based on 150 face-to-face interviews, will identify the most common issues affecting the haemophilia community. The second phase, based on a much larger data sample from 1,200 respondents, will illustrate how many people actually feel affected by the identified issues.

A range of psychosocial issues are currently discussed within the haemophilia community such as lack of self-esteem, impact on family life, living with pain and fear of a future with disabilities.

"Haemophilia has far-reaching consequences beyond the physical impact of the condition for people with haemophilia, their families and the people treating the condition," said Charlotte Ersbøll, corporate vice president for Global Stakeholder Engagement at Novo Nordisk. "This new programme will help us to better understand these broader effects on the haemophilia community."

"We are here to improve the lives of people with haemophilia and it is essential that their voice is heard," commented Frederica Cassis, psychologist at the Haemophilia Center of the Hospital das Clinicas, São Paulo, Brazil. "This unique study will give us valuable insights into the broad impact of this condition and will provide us with new tools to deal with the barriers of further improving haemophilia care."

About haemophilia
Haemophilia is a rare blood clotting disorder. Internal bleeding into the joints, muscles and other tissues can cause severe pain, joint damage and disability. The worldwide incidence of haemophilia A is approximately one case per 5,000 males, approximately 30% of whom have no family history. Haemophilia B occurs in one case per 25,000 males and represents 20–25% of all patients with haemophilia. It is estimated that around 400,000 males have haemophilia A or B.

About Novo Nordisk
Headquartered in Denmark, Novo Nordisk is a global healthcare company with 87 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. For more information, visit novonordisk.com.

Most Popular Now

AstraZeneca enters license agreement with KYM Bios…

AstraZeneca and KYM Biosciences Inc.* have entered into a global exclusive licence agreement for CMG901, a potential first-in-class antibody drug conjugate (ADC) targetin...

Pfizer receives positive FDA Advisory Committee vo…

Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that avail...

First nasal monoclonal antibody treatment for COVI…

A pilot trial by investigators from Brigham and Women's Hospital, a founding member of the Mass General Brigham healthcare system, tested the nasal administration of the ...

US FDA Advisory Committee votes to support effecti…

GSK plc (LSE/NYSE: GSK) announced that the US Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that the avail...

"Semantic similarity" leads to novel dru…

The words that researchers use to describe their results can be harnessed to discover potential new treatments for Parkinson's disease, according to a new study published...

Tumour cells' response to chemotherapy is driven b…

Cancer cells have an innate randomness in their ability to respond to chemotherapy, which is another tool in their arsenal of resisting treatment, new research led by the...

Engineered bacteria find tumors, then alert the au…

Combining discoveries in cancer immunology with sophisticated genetic engineering, Columbia University researchers have created a sort of "bacterial suicide squad" that ...

Nanosatellite shows the way to RNA medicine of the…

The RNA molecule is commonly recognized as messenger between DNA and protein, but it can also be folded into intricate molecular machines. An example of a naturally occur...

Gene and cell therapies to combat pancreatic cance…

Pancreatic cancer is an incurable form of cancer, and gene therapies are currently in clinical testing to treat this deadly disease. A comprehensive review of the gene an...

Digital twin opens way to effective treatment of i…

Inflammatory diseases like rheumatoid arthritis have complex disease mechanisms that can differ from patient to patient with the same diagnosis. This means that currently...

Pfizer's ZAVZPRET™ (zavegepant) migraine nasal spr…

Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) has approved ZAVZPRET™ (zavegepant), the first and only calcitonin gene-related peptid...

AI conjures proteins that speed up chemical reacti…

For the first time, scientists have used machine learning to create brand-new enzymes, which are proteins that accelerate chemical reactions. This is an important step in...